C.R. Bard Price Target Increased to $150.00 by Analysts at Raymond James (BCR)
Stock analysts at Raymond James raised their target price on shares of C.R. Bard (NYSE:BCR) from $140.00 to $150.00 in a report issued on Friday, Analyst Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price objective suggests a potential upside of 9.99% from the company’s current price.
Shares of C.R. Bard (NYSE:BCR) opened at 136.38 on Friday. C.R. Bard has a 52 week low of $93.79 and a 52 week high of $139.94. The stock’s 50-day moving average is $122. and its 200-day moving average is $112.4. The company has a market cap of $10.795 billion and a price-to-earnings ratio of 75.18.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported $1.50 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.40 by $0.10. The company had revenue of $758.00 million for the quarter, compared to the consensus estimate of $739.12 million. During the same quarter last year, the company posted $1.64 earnings per share. C.R. Bard’s revenue was up 4.9% compared to the same quarter last year. Analysts expect that C.R. Bard will post $5.79 EPS for the current fiscal year.
A number of other firms have also recently commented on BCR. Analysts at Zacks reiterated a “neutral” rating on shares of C.R. Bard in a research note to investors on Thursday, October 24th. They now have a $143.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of C.R. Bard from $126.00 to $142.00 in a research note to investors on Wednesday, October 23rd. They now have an “overweight” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of C.R. Bard from $130.00 to $140.00 in a research note to investors on Wednesday, October 23rd. They now have a “market outperform” rating on the stock. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $128.63.
In other C.R. Bard news, Director Herbert L. Henkel sold 2,400 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $134.66, for a total value of $323,184.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.